Sebastian Wicha
Annual Meetings
Save the Date
Antimicrobial Pharmacology Symposium
jointly organized by ISAP, EPASG and SIDP
Munich, Germany
16 April 2026
8:30-17:15
Conference Location
St. Vinzenz Haus of the LMU Hospital
Nußbaumstr. 5
80336 München

Anti-Infective PK/PD
Advancing Science and Collaboration
from Coffee to Dinner
Vienna, Austria
10th April 2025

|
© WienTourismus/Christian Stemper |
|
Sponsored by |

In cooperation with
Preliminary Program
09.00-10.00 ISAP Business Meeting (ISAP members only)
10.00-10.20 Registration for joint ISAP/EPASG meeting, coffee/tea
10.20-11.20 Plenary talk: Past, present and future of antimicrobial pharmacology –
How can we combat the AMR Crisis
Prof. Alasdair MacGowan (Consultant in Infection Research/Professor of Antimicrobial Therapeutics at North Bristol NHS Trust/Univ. of Bristol, UK)
11.20-12.20 Topic area I: Innovative treatment strategies
11.20-11.35 Unraveling Phage Pharmacodynamics Against KPC-5 Pseudomonas in the Hollow Fiber Infection Model
Thomas D. Nguyen et al., SUNY Buffalo, Buffalo, NY, USA
11.35-11.50 Efficacy of ganciclovir against CMV infection is dependent on treatment initiation time
Lalitya M. Sudarsono et al., Leiden University, Leiden, The Netherlands
11.50-12.05 Assessing the Therapeutic Potential of an Apramycin-Gallium Combination for Treating Acinetobacter baumannii Lung Infections
Anissa Benkhaled et al., Université de Poitiers, Poitiers, France
12.05-12.20 Model-based evaluation of an optimised meropenem dosing strategy in the intensive care unit
Nada Dia et al., KU Leuven, Leuven, Belgium
12.20-13.20 Lunch break
13.20-14.05 Bridging mechanistic research and clinical microbiology
Dr. Bartolome Moya (Balearic Islands Health Research Institute [IdISBa], Palma de Mallorca, Spain)
14.05-15.20 Topic area II: Antimicrobial PK/PD – Novel non-clinical findings
14.05-14.20 Dual AmpC and AmpD mutations in Pseudomonas aeruginosa: Unraveling the Mechanisms of Resistance to Ceftazidime and Avibactam
Albane Rozenholc et al., Université de Poitiers, Poitiers, France
14.20-14.35 Pharmacokinetic/pharmacodynamic modelling of immune response and meropenem activity in immunocompetent and neutropenic mouse lung infection models
Raphaël Saporta et al., Uppsala University, Uppsala, Sweden
14.35-14.50 Multifunctional Antimicrobial Peptide: A Promising Therapeutic for Cancer, Bacterial Infections, and Immune Modulation
Lukas Petrowitsch et al., University of Graz, Graz, Austria
14.50-15.05 A launching pad for next-generation therapeutics: Exploring mechanisms and biological profiles of novel OP-145 antimicrobial peptides
Altea Topciu and Nermina Malanovic, University of Graz, Graz, Austria
15.05-15.20 No time to waste: hospital-wide assessment of IV- vial and line residuals and impact on target attainment
Dorian Vanneste et al., KU Leuven, Leuven, Belgium
15.20-15.45 Coffee/tea break
15.45-16.30 How to optimize patient outcomes – PK/PD to support clinical dosing
Prof. Elisabet Nielsen (Uppsala University, Sweden)
16.30-18.00 Topic area III: Antimicrobial PK/PD: Novel clinical findings
16.30-16.45 Application of dried blood spot sampling for therapeutic drug monitoring of vancomycin and creatinine in the Outpatient Parenteral Antimicrobial Therapy service: a qualitative analysis of facilitators and barriers
Moska Hassanzai et al., Erasmus MC University Medical Centre – Rotterdam, The Netherlands
16.45-17.00 Ten years of susceptibility testing of linezolid in a tertiary care hospital: model-informed precision dosing as a strategy for rising resistance
Johannes Starp et al., LMU University Hospital, LMU Munich, Germany
17.00-17.15 Colistin population pharmacokinetic modelling and pharmacodynamic target attainment in critically-ill patients on with sustained low-efficiency dialysis
Dominika Fuhs et al., Monash University, Parkville, VIC, Australia
17.15-17.30 Isavuconazole pharmacokinetics in critically ill patients with acute-on-chronic liver failure and continuous hemodialysis: An observational study
Emily Behrens et al., University of Hamburg, Hamburg, Germany
17.30-17.45 Old friends, new foes: Explorative assessment of the potential drug-drug interaction between metamizole and mold-active azoles
Dorian Vanneste, KU Leuven, Leuven, Belgium
17.45-18.00 Enhanced Clearance of Broadly Neutralizing HIV-1 Antibody VRC07-523-LS Under Viremia: Influences on Trial Design and Analysis
Brian Ho et al., SUNY Buffalo, Buffalo, NY, USA
18.00-18.15 Trainee award ceremony
18.15-19.00 Travel to dinner venue – 10er Marie (oldest ‘Heuriger’ in Vienna)
19.30 Networking dinner
Organising Committee on behalf of ISAP and EPASG
Markus Zeitlinger* Jürgen Bulitta* (*conference chairs)
Iris Minichmayr Alina Nussbaumer-Pröll
Sebastian Wicha Cornelia Landersdorfer
Lena Friberg Zachary Bulman
Registration
The registration fees include lunch, coffee breaks and dinner (refunding registration fee is not possible)
Venue: Van Swieten Hall at the Medical University of Vienna
To register, please visit the Annual Meeting page on the ISAP homepage:
Abstract submission for young investigators
Submission deadline: February 28, 2025
Abstract format: ECCMID abstract format template (Word or pdf file):
(see https://www.escmid.org/congress-events/escmid-global/abstracts/guidelines-templates)
Send to:
Please indicate in your email which topic area I, II, or III the abstract belongs to (also see above:
I. Innovative treatment modalities, II. Novel non-clinical findings or III. Novel clinical findings)
Venue
Van Swieten Hall, Medical University of Vienna
Van-Swieten-Gasse 1a
1090 Wien

|
© https://www.meduniwien.ac.at/web/fileadmin/_processed_/1/1/csm_FEE_0040_29a5e4a7d4.jpg |
Welcome!
ISAP Annual Meeting 2024
We were honoured to be joined by Professor Gunnar Kahlmeter, sharing his inspiring career journey.

Continuing the custom, we had our ISAP Young Investigator session, chaired by Drs Vincent Aranzana-Climent (France), Rekha Pai Mangalore (Australia), Alina Nussbaumer-Pröll (Austria) and Sue C. Nang (Australia). We were thrilled to hear 15 exciting presentations from our young investigators.
Oral Presentations
|
Presenter |
Title |
|
Irene Hernández-Lozano Uppsala University, Sweden |
Model-informed drug-development for antimicrobials: translational PKPD modelling of apramycin to facilitate prediction of efficacious dose in complicated urinary tract infections |
|
Zhi Ying Kho Monash University, Australia |
Polymyxins differentially remodel human macrophage proteomic landscape in the presence and absence of bacterial infection |
|
Noémie Prebonnaud Université de Poitiers, Inserm U1070, France |
Linezolid and meropenem in vitro efficacy in artificial cerebrospinal fluid compared to Mueller-Hinton broth in hollow-fiber |
|
Aneeq Farooq University of Hamburg, Germany |
A pharmacometric model assessing the synergistic effect of bacteriophage-polymyxin combination therapy in a clinical multidrug-resistant K. pneumoniae isolate in vitro |
|
Alice Terrill Monash University, Australia |
Mechanism-based mathematical modelling predicts the effects of ciprofloxacin and meropenem on Pseudomonas aeruginosa with different resistance mechanisms in cases where PK/PD indices cannot |
|
Siobhonne Breen Monash University, Australia |
Ceftolozane/tazobactam and meropenem, in monotherapy and combination, against ST235 clone Pseudomonas aeruginosa isolates in the dynamic in vitro hollow-fibre infection model |
Rapid-Fire Talk
|
Presenter |
Title |
|
Farras Daffa Imtiyaz Université de Poitiers, Inserm U1070, France |
Adjuvant-loaded lipid nanoparticles to increase the susceptibility of Acinetobacter baumannii to colistin |
|
Jan Naseer Kaur University at Buffalo, USA |
Fine tuning polymyxin B based regimens to effectively tackle the growing threat of pan drug resistant Klebsiella pneumoniae |
|
Dominika Fuhs Monash University, Australia |
Mechanism-based modelling approach to simultaneously characterise the effects of single and multiple resistance mechanisms on bacterial killing and resistance emergence of Pseudomonas aeruginosa in response to meropenem |
|
Adrien Baillod Université de Poitiers, Inserm U1070, France |
Synergistic interaction between amphotericin B and azoles against Candida guilliermondii using pharmacodynamics-modelling approach |
|
Jess Tait Monash University, Australia |
Multi-omics informed mechanism-based model of meropenem plus tobramycin against clinical hypermutable Pseudomonas aeruginosa isolates in a hollow fibre infection model |
|
Annika Koumans Leiden University, Netherlands |
Interspecies interactions of cystic fibrosis-associated pathogens alter antibiotic pharmacodynamics |
|
Johannes Starp LMU University Hospital, LMU Munich, Germany |
Optimizing linezolid therapy in critical care: combining therapeutic drug monitoring and model-based approaches enhances target attainment |
|
Braira Wahid Monash University, Australia |
Tackling AMR with phage training: in vitro and in vivo evaluation of a trained phage against multidrug resistant Klebsiella pneumoniae |
|
Samar Ahmed California Northstate University, USA |
Potential synergy of fluoxetine and antimicrobials |
Many congratulations to Mr Aneeq Farooq and Ms Annika Koumans for wining the best oral presentation and rapid-fire talk awards, respectively!


Moving forward, Professor Juergen Bulitta (USA) will serve as the President for the term 2024 – 2026, with Professor Lena Friberg (Sweden) as the President-Elect.
It has been an amazing reunion for our ISAP community, and we look forward to seeing you again soon!


ISAP Annual Meeting 2023
This year, we were honoured to be joined by Professor Oana Ciofu as a Keynote Speaker to kick off the meeting with an insightful talk on the efforts to combat biofilm infections.

The meeting was followed by the traditional ISAP Young Investigator session, chaired by Dr. Vincent Aranzana-Climent, Dr. Iris Minichmayr and Dr. Sue C. Nang. It was fascinating to hear about the ground-breaking research conducted by our talented ISAP Young Investigators.
|
Presenter |
Title |
|
Noémie Prébonnaud Université de Poitiers, France |
Predicting antibacterial efficacy of linezolid on Staphylococcus aureus in cerebral infections using in vitro hollow fiber model and pharmacokinetic-pharmacodynamic modeling |
|
Aneeq Farooq University of Hamburg, Germany |
Pharmacokinetic/pharmacodynamic studies of meropenem combined with fosfomycin in a clinical K. pneumoniae isolate expressing KPC-2 carbapenemase and fosfomycin resistance |
|
Mathilde Lacroix Université de Poitiers, France |
Transcriptomic data to support in vitro semi-mechanistic PK/PD modelling of polymyxin B against Acinetobacter baumannii |
|
Chenyan Zhao Uppsalla University, Sweden |
Characterizing bacterial growth and killing kinetics of RG6006 using in vitro and in vivo time-kill studies and mechanism-based pharmacokinetic-pharmacodynamic (PKPD) modeling |
|
Thomas D. Nguyen University at Buffalo, USA |
Developing a mechanistically informed population pharmacokinetic model of vancomycin in patients undergoing intermittent hemodialysis |
|
Augustine Koh Melbourne University, Australia |
Investigating Leu10Teixobactin combinations with glycopeptides against multidrug-resistant Gram-positive pathogens |
|
Eva Wehrhahn Uppsalla University, Sweden |
Quantification of antibiotic-induced changes in bacterial counts and morphology using timelapse microscopy, image analysis, machine learning and pharmacokinetic-pharmacodynamic modelling |
|
Malin Andersson Freie Universität Berlin, Germany |
Beyond the standard ratio: Quantitative exploration of the effect of piperacillin with varying tazobactam concentrations |
|
Gert-Jan Wijnant Université catholique de Louvain, Belgium |
Population pharmacokinetics and dosing simulation of the β-lactam temocillin in liver-transplanted pediatric patients |
|
Hélène Thirot Université catholique de Louvain, Belgium |
Linezolid toxicity in clinical practice: Towards a better detection of at-risk patients? Interim analysis of a prospective multicentric study |
|
Maria Sanz-Codina Medical University of Vienna, Austria |
Plasma and soft tissue pharmacokinetics of cefiderocol in healthy volunteers |
Congratulations to the winners of the Young Investigator session:
Oral presentation: Mr. Aneeq Farooq (University of Hamburg, Germany)

Rapid fire talk: Dr. Gert-Jan Wijnant (UCLouvain, Belgium)

We were delighted to see many of you in Copenhagen and we look forward to seeing you again next year!

Optimised dosing of antibiotics – understanding PK/PD, clinical breakpoints and therapeutic drug monitoring
A 2 day course on PK/PD of anti-infectives was held as a pre-meeting to ECCMID at April 20 -21 2022 in Lisbon, Portugal. The course was organized in collaboration with EPASG and very well attended.

The program of the course can be found here.
ISAP General and Scientific Meeting
Immediately following the educational course, we held our general meeting and reflected on our scientific and educational acitivities of the past two years, followed by the traditional ISAP Young investigator session, chaired by Dr. Alina Nussbaumer-Pröll (Vienna) and Dr. Vincent Aranzana-Climent (Poitiers).
The slides of the general meeting can be found below. Access is restricted to ISAP members (please login to view attachment).
The following Young Investigators presented their work:
|
First name |
Last Name |
Title |
|
Aneeq |
Farooq |
Interaction screening of ceftazidime-avibactam and tigecycline against six clinical and nine isogenic E. coli and K. pneumoniae strains expressing carbapenemases |
|
Wisse |
Van Os |
Impact of individual ascitic fluids on bacterial growth and ceftriaxone effect in an in vitro model of spontaneous bacterial peritonitis |
|
Nicole |
Zimmermann |
Integrated in vitro approach to understand the exposure-effect relationship of fosfomycin against Escherichia coli |
|
Amaury |
O'Jeanson |
A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against β-lactamase-producing Gram-negative bacteria |
|
Jinxin |
Zhao |
PhageGE: An Interactive Web-based R Shiny Application for Bacteriophage Pharmacology |
|
Sue |
Nang |
Elucidating the pharmacokinetics/ pharmacodynamics of bacteriophage therapy against Pseudomonas aeruginosa using a mouse bacteraemia model |
|
Romain |
Aubry |
Semi-mechanistic PKPD modelling of ceftazidime/avibactam and colistin combination against five multidrug resistant Klebsiella pneumoniae isolates |
|
Mathilde |
Lacroix |
In vitro PK/PD modelling of polymyxin B against resistant strain of A. baumannii in presence of mucin |
|
Matthias |
Gijsen |
Model-based TDM of vancomycin: a retrospective comparison with routine TDM-based dosing |
|
Gert-Jan |
Wijnant |
Pharmacokinetics and PK/PD of temocillin in non-ICU urinary tract infection patients with various stages of renal insufficiency |
|
Tim |
Ewoldt |
Large variability of unbound active fraction of ceftriaxone in contrast to ciprofloxacin in plasma of critically ill patients |
|
Maria |
Sanz Codina |
Relationship between pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill COVID-19 patients with documented Gram-negative superinfections treated with meropenem continuous infusion |

ISAP Young Investigators
The audience voted for the best Young Investigator presentations:
Wisse Van Os (Medical University of Vienna, Austria)
Gert-Jan Wijnant (UCLouvain, Belgium)

The winner of the Young Investigator session Wisse van Os (3rd from left) and runner-up Gert-Jan Wijnant (3rd from right) together with the Young Investigator session chairs Alina Nussbaumer-Pröll and Vincent Aranzana Climent (right) and Sebastian Wicha (President of ISAP) and Markus Zeitlinger (Chair of EPASG) (left).

All attendees of the ISAP meeting.
The ISAP 2021 meeting was held as a full day virtual conference in collaboration with EPASG on Friday, November 12 2021 - Saturday November 13 2021 as a online meeting.
Program
Sebastian Wicha
Young Investigator session awards
As per the ISAP tradition, Young Investigators presented their research in the traditional Young Investigator session. The presentation topics ranged from pre-clinical, mechanistic PK-PD studies up to clinical applications of PK-PD. All research was presented very comprehensively and to the highest scientific standards.
The attendees voted the best three presentations who recieved the Young Investigator Awards 2021:
|
Winner: Vincent Aranzana-Climent (Uppsala University, Sweden) |
Runner-ups: Khalid Iqbal (University of Hamburg, Germany) Anselm Jorda (Medical University of Vienna, Austria) |
![]() |
![]() |
The ISAP 2020 meeting was held as a virtual meeting on Friday, September 18th, 12:00pm to 2:00pm (CEST) as an online meeting.
Schedule
| 11:30 to 12:00pm | Council meeting (closed) |
| 12:00 to 12:30pm | General Meeting: Welcome, ISAP discussion, and New Officers |
| 12:30 to 2:00pm | Young Investigator Session |
ISAP Council and General Meeting
Retirement of Council members
The Council for the term 2018-2020 comprised:
- Brian Tsuji (President)
- Sebastian Wicha (President-Elect)
- Zackery Bulman (Treasurer)
- Jian Li (Secretary)
- Council members: Hartmut Derendorf, Lena Friberg, Elizabeth Lakota, Justin Lenhard, Elisabet Nielsen, Roger Nation, Ursula Theuretzbacher, Markus Zeitlinger
In the light of many new nominations, Roger Nation, Hartmut Derendorf, Ursula Theuretzbacher, Elizabeth Lakota and Justin Lenhard retired from Council to provide new members the op
portunity to serve ISAP. With Ursula, Hartmut, and Roger, three former presidents of ISAP and longstanding ISAP members leave the Council.
Brian thanked all retiring Council members for their outstanding services to ISAP, without whom the society would not be the same as it is today.
All members thanked Brian Tsuji for his amazing work he has done as President and beyond. He provided a collegial leadership to ISAP, was a huge supporter of all Young Investigator activities and organized scientific symposia and strategically liaised new collaborations for ISAP. THANK YOU, Brian!
Election of Council members for the term 2020-2022
- Sebastian Wicha (President)
- Jian Li (President Elect)
- Zack Bulman (Treasurer)
- Elisabet Nielsen (Secretariat)
- Iris Minichmayr (Secretariat)
- Council members: Lena Friberg, Markus Zeitlinger, Brian Tsuji, Jürgen Bulitta, Cornelia Landersdorfer, Alina Nussbaumer-Pröll, Nicholas Smith
It is a great to have so many new members on board to join and shape the future of ISAP!
Update on ISAP activities
PKPD Webinar (in collaboration with EPASG) – SAVE THE DATE: November 24 2020 –
In collaboration with EPASG, there will be a webinar on “Modeling SARS-Cov-2 viral dynamics to optimize therapy”, by Dr Jeremie Guedj from INSERM, Paris, France held on November 24 2020 4PM CET. The details to join the meeting will be provided in another newsletter. Welcome!
ASCPT Pre-Conference 2020
A pre-conference to the ASCPT meeting titled “Translational and Clinical Pharmacology Advances in Anti-Infective Development” was planned for March 18 2019 in collaboration with ASCPT and SIDP. The ISAP contribution was organized by Hartmut Derendorf. A number of ISAP speakers (Lena Friberg, Corneial Landersdorfer, Sebastian Wicha) were scheduled for contributing presentations to the pre-conference. No follow up meeting is planned at this stage, but instead a call for papers to a special issue on Anti-Infectives has been launched in Clinical Pharmacology & Therapeutics. Read more here, in case you wish to contribute.
Antimicrobial Pharmacology at ISICEM 2020 – scheduled for Autumn 2021
ISAP contributed a clinically-oriented session on “Pharmacology of Antibiotics” to the International Symposium on Intensive Care & Emergency Medicine (ISICEM). Iris Minichmayr and Sebastian Wicha were scheduled to contribute presentations on PKPD relationships of antibiotics and interactive case studies for dose individualization. At this stage, the conference is re-scheduled for March 2021. Read more here, in case you are interested to attend.
Face-to-face Meeting(s) 2021
As you all know, the current situation makes it difficult to predict if we can meet in person next year. Potential candidates for a face-to-face meeting are pre or post ECCMID (Vienna, 9-12 July 2021) or a US-based meeting. We will keep you informed.
Online meetings
We are planning a series of regional online meetings to foster scientific exchange between ISAP members. Stay tuned.
Scientific Meeting of ISAP – Young Investigator session
As per the ISAP tradition, also in our virtual meeting, Young Investigators presented their research in the traditional Young Investigator session. The presentation topics ranged from pre-clinical, mechanistic PK-PD studies up to clinical applications of PK-PD. All research was presented very comprehensively and to the highest scientific standards. Congratulations to all Young Investigators!
| Presenter | Title |
| Zhi Ying Kho | Omics of the tripartite relationships among Acinetobacter baumannii, polymyxin and macrophage |
| Jinxin Zhao | Genome-scale metabolic modelling of multidrug-resistant Acinetobacter baumannii revealed significant metabolic changes during bloodstream infection in mice |
| Niklas Krömer | Adaptive optimal design to support efficient high throughput screening of in vitro pharmacodynamic drug interaction studies |
| Alina Nussbaumer-Pröll | Comparison of dosage strategies of meropenem vs. Escherichia coli and Pseudomonas aeruginosa |
| Tan Xing | Activity of simulated ELF concentrations of inhaled and intravenous tobramycin and polymyxin B against Pseudomonas aeruginosa in an in vitro dynamic biofilm model |
| Hubert Chjua | Antiretroviral and β-lactam Combinations against NDM-Producing Klebsiella pneumoniae: Repurposing Zidovudine as Salvage Therapy |
| Anders Thorsted | Translational modelling of innate immune response following lipopolysaccharide challenge: from piglets to humans |
| Josefine Schulz | Feasibility investigations of simultaneous microdialysis of voriconazole and its N-oxide metabolite |
| Luis Ilia | Identification and quantification of microdialysis variability using an integrated in vitro, ex vivo and in silico approach. |
| Anne-Grete Märtson | Caspofungin weight-based dosing |
EPASG-EUCAST-ISAP course
Optimised dosing of antibiotics – understanding PK/PD, clinical breakpoints and therapeutic drug monitoring
A 2 day course on PK/PD of anti-infectives was held as a pre-meeting to ECCMID at April 11 -12 2019 in Rotterdam, The Netherlands. The course was organized in collaboration with EPASG and EUCAST and very well attended.

Scientific Meeting of ISAP
Standing on the Shoulder of Giants: A Tribute to Alan Forrest.
This year’s ISAP scientific meeting started with a session remembering Alan Forrest, who passed away in August 2018. Alan was a wonderful friend, mentor, colleague and a true inspiration to our community and beyond. In this open session, a number of ISAP members shared personal and scientific memories of Alan with the attendees.
![]() |
![]() |
| Brian Tsuji | Roger Nation |
Young Investigator Session
Immediately following the educational course, a Scientific Meeting was held in association with EPASG. As per the ISAP tradition, the meeting focused on the presentation of the research of Young Investigators. With 12 presentations from Young Investigators, a diverse group of studies in antimicrobial PKPD was discussed by the knowledgeable speakers. The slides of the presentations can be found in the Archive (available after login for ISAP members).
Young Investigator presentations:
|
Presenter |
Title |
|
Vincent Aranzana-Climent |
Use of a semi-mechanistic PK-PD model to quantify the combination effect of polymyxin B and minocycline against polymyxin-resistant Acinetobacter baumannii |
|
Xiaoting Hua |
Formation and evolution of multi-drug resistance plasmid in Proteus mirabilis |
|
Ahmed M. Fathalla |
Polymyxins co-localise with different cellular organelles in human macrophages |
|
Jessica R. Tait |
Piperacillin/tazobactam plus tobramycin against a clinical Pseudomonas aeruginosa isolate: optimising combination dosage regimens in a dynamic in vitro infection model |
|
Johanna Seeger |
Exploring the exposure-effect relationship of levofloxacin against fluoroquinolone resistant Escherichia coli isolates in a dynamic in vitro infection model |
|
Hajira Bilal |
Pharmacodynamics of meropenem - tobramycin combination dosage regimens against clinical hypermutable Pseudomonas aeruginosa at simulated epithelial lining fluid concentrations in a dynamic biofilm model |
|
Shachi Mehta |
“PK/PD” type of modelling approach to support time-kill data interpretation of cefoxitin for the treatment of Mycobacterium abscessus |
|
Alina Nussbaumer-Pröll |
Comparison of antimicrobial activity and pathogen mutation prevention of originator and generics of cefepime, linezolid and piperacillin-tazobactam |
|
Khalid Iqbal |
Towards target site-specific breakpoints combining microdialysis, time-kill curves and physiologically based pharmacokinetic (PBPK) modelling: A case study with moxifloxacin |
|
Sebastian Franck |
Boosting the immune system to enhance amoxicillin activity: Insights provided by semi-mechanistic PK/PD modelling |
|
Jinxin Zhao |
Battle to the end: uncover the interplay among the host, pathogen and polymyxin in a murine Acinetobacter baumannii bacteremia model by the dual transcriptome analysis |
|
Dinh H. Vu |
Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: population pharmacokinetic modelling and simulation |
Congratulations to Sebastian Franck (Freie Universität Berlin / University of Hamburg, Germany) who received the newly introduced Alan Forrest Young Investigator Award for the overall best presentation. Congratulations to Shachi Metha (University of Poitiers, France) and Alina Nussbaumer-Pröll (Medical University of Vienna, Austria) for winning the two runner-up awards in this session.

Markus Zeitlinger (Chair of EPASG), Zackery Bulman and Sebastian Wicha (Chairs of the ISAP Young Investigator Session), Shachi Metha (Young Investigator Award winner), Thomas Tängdén (Treasurer of EPASG), Sebastian Franck (Alan Forrest Young Investigator Award winner), Alina Nussbaumer-Pröll (Young Investigator Award winner) and Brian Tsuji (President of ISAP).

All participants of the 2019 ISAP Meeting
Social Reception
The meetings above were followed by a social gathering in the lobby of the conference hotel Blijdorp Rotterdam to discuss latest news on PK-PD and beyond and to meet old and new colleagues and friends.
![]() |
![]() |
![]() |
![]() |
ISAP Council Meeting and General Meeting
Retirement of Council members
The current Council was elected in 2016 and comprises:
- Roger Nation (President)
- Brian Tsuji (President Elect and Treasurer)
- Ursula Theuretzbacher (Immediate Past President)
- Lena Friberg and Sebastian Wicha (Joint Secretariat)
- Council members: Hartmut Derendorf, Justin Lenhard, Johan Mouton, Vincent Tam and Markus Zeitlinger
- Young Investigator Liaison: Justin Lenhard and Sebastian Wicha
In view of the healthy number of people who nominated for the next Council, Johan Mouton and Vincent Tam kindly offered to retire from Council to provide opportunity for others to serve ISAP.
An amazing feat is that Johan has been on Council for 20 years, with a substantial portion of that time serving as a member of the executive. Indeed, Johan was President Elect of ISAP from 2000 to 2002, President from 2002 to 2004 and Immediate Past President from 2004 to 2006.
Vincent has served on Council for 10 years, with 8 of those years as Treasurer. Both Johan and Vincent have made an enormous contribution not only to ISAP Council but also to the activities of ISAP more generally (e.g. as key contributors to ISAP educational workshops and conference symposia) and to the discipline.
On behalf of all members of ISAP, Roger and other Council members would like to thank Johan and Vincent for their dedicated service and collegiality, and for their kind offer to provide ongoing support to the Councils of the future. Roger would like to take this opportunity to thank all members of ISAP Council for their wonderful support over the last two years. Of special note is Brian who has been an outstanding President Elect; he will be equally outstanding when he takes on the role of President. Brian would like to thank Roger for the work he has done as President. He has provided compelling leadership to ISAP which has expanded membership, organized key educational symposia, liaised strategic collaborations and allowed ISAP to reach new heights of excellence. Roger’s hard work, dedication and passion for ISAP is extremely inspiring to us all. With most sincere gratitude from all of us to our fearless and amazing leader – Roger Nation!
Election of Council members for the next two years
There was an excellent response to the call for nominations for membership of the next ISAP Council and for the executive officer positions. The composition of the next Council is as follows:
- Brian Tsuji (President)
- Sebastian Wicha (President Elect)
- Roger Nation (Immediate Past President)
- Jian Li (Secretary)
- Zack Bulman (Treasurer)
- Council members: Hartmut Derendorf, Lena Friberg, Elizabeth Lakota, Justin Lenhard, Elisabet Nielsen, Ursula Theuretzbacher and Markus Zeitlinger
It is truly wonderful to have Jian, Zack, Elizabeth and Elisabet join ISAP Council. The membership of the new Council was ratified by the ISAP members who attended the General Meeting in Madrid. The new Council will commence its term in June 2018.
ISAP Honorary Life Membership Recipient: Professor Otto Cars

At the General Meeting in Madrid, Professor Otto Cars was announced as the recipient of Honorary Life Membership of ISAP. In accordance with ISAP Bylaws, appointment to Life Membership was made on the recommendation of Council. Below is a very brief summary of Otto’s outstanding career, including his key role in creating and nurturing ISAP and his contribution to optimizing the use of antimicrobials and preserving their usefulness for generations to come.
- Otto Cars was a founding member of ISAP

- Along with Dr William Craig, Otto organized a landmark meeting in Copenhagen in 1989 that led to ISAP being created in 1991 (see black and white photo)
- Otto was the second President of ISAP (1994 - 1996) following the term of William Craig as the initial President (1991 - 1994)
- Otto became a specialist in infectious diseases in the early 1970s
- He was appointed Head of the Department of ID at Uppsala University Hospital 1991-1999
- In 2003, Otto became Professor of ID at Uppsala University
- Otto’s research over the years has focussed on PK and PD of antibiotics, optimal antibiotic dosing regimens, resistance epidemiology and antibiotic policies
- Otto has published extensively and is highly respected for the quality and the impact of his work
- He initiated and/or was a driving influence in numerous Swedish, European and international initiatives to preserve the usefulness of antibiotics (e.g. Member of the WHO Strategic and Technical Advisory Group on Antimicrobial Resistance (STAG-AMR); Founding Director of ReAct in 2005, and since 2013 he is now a senior strategic adviser; Expert member on the recently created UN / WHO Interagency Coordination Group on Antimicrobial Resistance)
- Otto has been the recipient of numerous awards for his services to medicine and science (e.g. he was awarded the highly prestigious King’s Medal in 2015)
Interactions with other organizations
On behalf of ISAP, Ursula Theuretzbacher and Sebastian Wicha delivered a 1-hour interactive workshop to ca. 300 participants at the 18th International Congress on Infectious Diseases held in Buenos Aires in March. After an introduction into PK/PD concepts and targets, participants were actively involved in an interactive session. On their mobile devices or laptops, they used the TDMx web application as an example of a precision dosing tool to work on several tasks around dose individualization of β-lactam antibiotics. The session was a great success and the diverse audience (mainly physicians, pediatricians, pharmacists, microbiologists) from all parts of the world seemed to be able to follow the instructions and to experience how PK and PD variables influence dosing decisions.
At the ASM Microbe conference in Atlanta USA in June, ISAP is delivering a pre-conference workshop entitled ‘Introduction to Pharmacokinetics-Pharmacodynamics: A Basic Primer’. The workshop is being delivered by Brian Tsuji, Hartmut Derendorf, Elizabeth Lakota, Vincent Tam and Roger Nation. A Young Investigator night out for ISAP in collaboration with ISoP is being planned by Elizabeth Lakota on Friday June 8 in the late evening. More details will be posted on the ISAP website as the date approaches.
Following the ECCMID meeting in Madrid this year, ISAP worked with EPASG to deliver an oral presentation session within the scientific program of the 3rd International Conference on Polymyxins. ISAP is actively engaged in planning a joint initiative with EPASG and EUCAST to hold an educational / scientific meeting as a satellite to the ECCMID meeting to be held in Amsterdam in April 2019. ISAP and EPASG have held highly successful joint meetings in the past, including the day prior to the ECCMID meeting in Vienna last year.
ISAP Council is very eager to join with other organizations in submitting proposals for symposia and educational workshops at major conferences in various parts of the world. A number of possibilities are under active consideration.
Endorsement of Polymyxin Dosing Guidelines
A unique opportunity for ISAP presented itself to endorse the Polymyxin Guidelines which will be published in Pharmacotherapy and will appear as executive summaries in other journals. ISAP will be endorsing the guidelines along with 6 other international organizations. The guidelines have been accepted by Pharmacotherapy and will be published soon.
ISAP finances and membership
The financial situation of ISAP is healthy and the membership is growing. However, it is very important for members to respond to the call for payment of the annual membership fee. ISAP is not a large organization and it is a time-consuming challenge to send reminder emails to members to prompt them to pay their annual membership subscription. In this regard, the cooperation of all members would be greatly appreciated. It would also be helpful if you would assist in recruiting new members from within your institutions and networks of scientific and clinical colleagues.
Scientific Meeting of ISAP
Immediately following the General Meeting in Madrid, a Scientific Meeting was held in association with EPASG. As per the ISAP tradition, the meeting focused on the presentation of the research of Young Investigators. With 13 presentations from Young Investigators, a diverse group of studies in antimicrobial PKPD was discussed by the knowledgeable speakers. Congratulations to Iain Abbott, Astrid Brӧker, and Nicholas Smith for receiving Young Investigator Awards for their excellent presentations.

All participants of the 2018 ISAP Meeting

Justin Lenhard (chair of the Young Investigator session), Roger Nation (President of ISAP), Iain Abbott, Astrid Bröker and Nicholas Smith (Young Investigator Awardees) and Sebastian Wicha (chair of the Young Investigator session).
Social Reception
The meetings above were followed by a social gathering held in collaboration with the 3rd International Conference on Polymyxins, EPASG and the Spanish Infectious Diseases Society. Approximately 100 people attended this function which provided the opportunity for ISAP members to socialize with their colleagues, meet potential new collaborators and enjoy light appetizers and liquid refreshments.

Young Scientist Night Out in Madrid
The night prior to the General Meeting young scientists who participate in ISAP were invited to an informal gathering to network and enjoy the nightlife of Madrid. Over 10 attendees met at the Del Diego Cocktail Bar to mingle and make new connections with peers in the field. Considering the success of the event, ISAP will likely host similar functions in conjunction with future meetings.

ISAP-EPASG Conference in Vienna a Major Success
On 21 April, the day before the start of the 2017 ECCMID meeting, ISAP held a joint one-day conference with EPASG (the ESCMID PK/PD of Anti-infectives Study Group). The conference was entitled ‘Anti-infective PK/PD: Integrating Knowledge and Innovating Therapies’ and was held in the historic Old General Hospital Vienna. The program included sessions on key topics such as antimicrobial resistance, combination therapy and the role of the immune system. Informative and entertaining ‘pro’ / ‘con’ debating sessions on topics such as the future role of modelling versus clinical studies in the development and optimization of dosing of antimicrobials enhanced the program. A special feature of the day’s activities was a ‘Young Investigator’ session, which included presentations from 16 up and coming researchers, the largest number ever for such an ISAP session. All young investigators performed very well and the judges had great difficulty in deciding the recipients of awards. Overall, the first-placed awardee was Tobias Heinrichs, while Iris Minichmayr, Amelia Deitchman, Alexia Chauzy and Nikolas Onufrak also received awards. The ‘Young Investigator’ session continued the ISAP tradition of providing a forum for the emerging researchers of our discipline to deliver oral presentations of their research in a supportive setting and receive constructive feedback. The conference was supported by Basilea and Roche (main sponsors) and Nabriva and AntibioTx (sponsors).

There were 120 attendees at the conference, a capacity crowd for the venue. Members of ISAP and EPASG (note that members of ESCMID can apply for free membership of EPASG) received discounted registration for the conference. Attendees at the conference indicated that they greatly enjoyed the day of antimicrobial pharmacological science. The day concluded with a wonderful dinner at a lovely heuriger in Vienna, and the presentation of awards to young investigators (see photo). This social event was kindly supported by the Mayor of Vienna.
The conference would not have been possible without the tireless efforts of our Viennese colleagues Markus Zeitlinger and Ursula Theuretzbacher (conference chairs), with support from Alina Proll. The contributions of all members of the conference organizing committee, the speakers and chairs, Jacqueline van der Meer (Congress Care) and the sponsors are gratefully acknowledged.
Young Investigator awardees Tobias Heinrichs (3rd from left), Nikolas Onufrak (1st from left), Iris Minichmayr (5th from left), Alexia Chauzy (2nd from right) and Amelia Deitchman (1st from right) along with Justin Lenhard and Sebastian Wicha (4th and 3rd from right, Chairs of the Young Investigator session) and Markus Zeitlinger (4th from left) and Ursula Theuretzbacher (2nd from left).
The 2015 ISAP symposium took place after the ICAAC and before the Polymyxin Conference in a wonderful conference site in La Jolla near San Diego. The first part of the symposium was dedicated to the memory of Prof. William Craig and looking back to the achievements of our field whereas the second part of the afternoon was dedicated to the future of anti-infective pharmacology. A planned publication will summarise our vision for the future of our field.
Similar to previous years the short presentations of young investigators where interesting, well received and discussed. Seven presentations were selected for presentation. Three young investigators – Amelia N. Deitchman, Justin Lenhard and Sebastian Wicha were awarded with travel grants for their work and the presentations. Mentoring young researchers and providing a friendly and supportive environment for discussing their work is one of ISAP's main goals as well as organising workshops at major conferences.
General Assembly: 1:00-2:00 PM
Preliminary program - ISAP symposium:
| 2:10-2:15 PM | Introduction Ursula Theuretzbacher, Paul Ambrose |
|
| Looking back: Achievements in anti-infective pharmacology Chair: Francoise van Bambeke |
||
| 2:15-2:30 PM | David Andes: Tribute to Bill Craig | |
| 2:30-2:50 PM | Paul Tulkens: Lecture in memoriam Bill Craig 24 years of ISAP - Achievements in the PK/PD field |
|
| Looking forward: A critical focus for the next decade - A roadmap for research from an anti-infective pharmacology perspective Chair: Hartmut Derendorf, Vincent Tam |
||
| 2:50-4:00 PM | - How can the discipline of anti-infective pharmacology contribute to optimizing antimicrobial use in the future? - What are the new horizons? - What are the critical preclinical, translational and clinical research questions? - What do we need in the anti-infective pharmacology toolbox, in addition to PK/PD? Short kick-off presentations intended to provoke discussion about the future of anti-infective pharmacology. Panellists are asked to briefly address one or more of the above questions. Structured panel discussion and audience participation Panellists: Lena Friberg, Jürgen Bullita, Brian Tsuji, Jian Li, George Drusano, Jason Roberts, Johan Mouton, Paul Ambrose |
|
| 4:00-4:20 PM | Networking coffee break | |
| 4:20-5:45 PM | Presentations of young investigators Chair: Brian Tsuji |
|
| 5:45-5:50 PM | Farewell: Roger Nation, Ursula Theuretzbacher | |
| 6:00 PM |
Networking reception |
|

Program:
| 12:00 - 1:00 pm 1:00 - 1:45 pm |
ISAP Council Meeting ISAP General Meeting |
2:00 – 2:10 pm |
Welcome |
| 2:10 – 3:10 pm |
Scientific presentation and discussion PK/PD in the regulatory environment Joga Gobburu, University of Maryland, School of Pharmacy, former head of pharmacometrics at FDA |
| 3:10 - 3:40 pm |
Break / informal discussion |
| 3:40 – 5:40 pm |
Scientific presentations by junior investigators |
| 5:40- 6:00 pm |
Discussion and closing remarks |
Scientific presentations by junior investigators
| MW. Sadiq | A whole-body physiologically based pharmacokinetic model of ciprofloxacin for prediction of bacterial killing at the site of infection |
| S. Aitken | Cefepime free minimum concentration to minimum inhibitory concentration ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia |
| T-P. Lim | Multiple combination bactericidal testing-guided therapy is effective in the treatment of extensively drug-resistant Gram-negative bacteria infections |
| E. Bassères | Antibiotic activity against different Pseudomonas aeruginosa phenotypes in an artificial sputum medium biofilm model |
| A. Sultan | Bayesian estimation of levofloxacin pharmacokinetics in patients with tuberculosis |
Online presentations (will be posted after ICAAC):
| A. Deitchman | The synergism between tigecycline and tetracycline: A protein binding-based approach |
| S. Wicha | Pharmacodynamics of vancomycin or linezolid combined with meropenem against Staphylococcus aureus assessed by descriptive and semi-mechanistic modelling techniques |
Download program

Program:
| 12:00 - 1:00 pm 1:00 - 1:45 pm |
ISAP Council Meeting ISAP General Meeting |
2:00 – 2:10 pm |
Welcome |
| 2:10 – 3:20 pm |
Scientific presentation and discussion PK/PD approach in industry vs academic settings
|
| 3:20 - 3:50 pm |
Break / informal discussion |
| 3:55 – 5:35 pm |
Scientific presentations by junior investigators |
| 5:40- 6:00 pm |
Discussion and closing remarks |
Scientific presentations by junior investigators
| Time | Presenting author | Title |
| 3:55pm | Seyedmousavi | Posaconazole Prophylaxis in Experimental Azole-resistant Invasive Pulmonary Aspergillosis |
| 4:20pm | Trang | Initial Dosing and an Adaptive Feedback Control Algorithm for Renal Replacement Patients during Drug Development |
| 4:45pm | Vandevelde | Combinations of moxifloxacin with bronchodilators are synergistic against S. pneumoniae in models of naïve and induced biofilms |
| 5:10pm | Zhuang | Characterization of the in vitro antimicrobial activity of vertilmicin alone and in combination with ceftazidime using a semi-mechanistic pharmacokinetic/pharmacodynamic model |
Registration on site:
- ISAP members: free
- Non-members: 100 Euro including one year ISAP membership
Coffee, beverages and snacks will be served.
- PK/PD special topic:
Jason Roberts: Translational aspects of PK/PD tools for personalized dosing in the ICU - Forum for Young investigators: Brief presentations on PK/PD topics related to old and new anti-infectives
| 12:00 - 13:00 13:00 - 13:45 |
ISAP Council Meeting ISAP General Meeting |
|
| 14.00 - 14:05 14:05 - 15.15 |
Welcome Scientific presentation and discussion Jason Roberts: Translational aspects of PK/PD tools for personalized dosing in the ICU Discussion |
|
| 15.15 - 15.40 | Break / Informal discussion | |
| 15.40 - 17.55 | Scientific presentations by junior investigators Discussion, feedback |
|
| 18.00 | Closing remarks |
More information on the scientific presentations

The Annual Meeting and post-ICAAC symposium took place on Tuesday, September 20th,
Hyatt Regency, McCormick Place, Chicago, IL
Program










